Real‐world effectiveness of highly purified cannabidiol in epilepsy associated with 15q11.2‐q13.1 duplication and deletion syndromes: A multicenter study
This multicenter retrospective study evaluated the effectiveness and safety of highly purified cannabidiol (CBD) in 22 patients with 15q11.2-q13.1 duplication or deletion syndromes (15q-DDS), including 12 with 15q duplication syndrome (dup15q) and 10 with Angelman syndrome (AS). Median (interquartile range [IQR]) age at CBD initiation was 14.5 (10-22.5) years, with a median (IQR) follow-up of 21 (14-33) months. All dup15q and two AS patients presented with a Lennox-Gastaut phenotype. At last observation, mean seizure reduction was 55.7% (95% confidence interval 38.7-72.7), with 63.6% patients achieving ≥50% reduction, 40.9% achieving ≥75% reduction, and 18.2% achieving seizure freedom. Tonic seizures in dup15q and myoclonic seizures in AS showed the most notable reductions. EEG improvement was observed in 7/16 patients, with marked improvement observed in two dup15q patients. Clinical improvement on the Clinical Global Impression-Improvement scale was reported in 72.7%, alongside nonseizure benefits such as improved sleep, behavior, and attention in a subset of patients. CBD was well tolerated; no patient discontinued CBD due to side effects alone, and retention at last visit was 81.8%. These findings suggest that CBD may provide clinically meaningful benefit in patients with 15q-DDS, including seizure reduction and improvements in sleep, behavior, and attention in selected cases. PLAIN LANGUAGE SUMMARY: Epilepsy secondary to 15q11.2-q13.1 duplication or deletion syndromes (15q-DDS) is often severe, making daily life difficult for patients and their families. In this study, treatment with highly purified cannabidiol (CBD) reduced seizures in many patients with 15q-DDS. CBD was generally well tolerated, and caregivers also reported improvements in sleep, behavior, and attention in a number of cases. Overall, these findings suggest that CBD may be a helpful treatment option for people with 15q-DDS.
Authors
- Susanna Negrin (ORCID: https://orcid.org/0000-0003-4118-1795)
- Domenica Battaglia (ORCID: https://orcid.org/0000-0003-0491-4021)
- Erica Cognolato (ORCID: https://orcid.org/0000-0001-8064-5738)
- Emanuele Cerulli Irelli (ORCID: https://orcid.org/0000-0003-3906-555X)
- Irene Bagnasco
- Georgia Ramantani (ORCID: https://orcid.org/0000-0002-7931-2327)
- Adolfo Mazzeo (ORCID: https://orcid.org/0000-0002-7014-6617)
- Marco Perulli (ORCID: https://orcid.org/0000-0003-3311-2765)
- Alessandro ORSINI
- Antonietta Coppola (ORCID: https://orcid.org/0000-0002-4845-4293)
- Francesca F. OPERTO
- Carlo Di Bonaventura (ORCID: https://orcid.org/0000-0003-1890-5409)
- Pasquale Striano (ORCID: https://orcid.org/0000-0002-6065-1476)
- Alberto Danieli
- Paolo Bonanni
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Istituto Giannina Gaslini (IT)
- Agostino Gemelli University Polyclinic (IT)
- Federico II University Hospital (IT)
- University Children's Hospital Zurich (CH)
- Ospedale Martini (IT)
- IRCCS Eugenio Medea (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- University of Genoa (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Epilepsia Open
- Published
- 2026-04-16
- DOI
- https://doi.org/10.1002/epi4.70241
- Primary Topic
- Genetic Syndromes and Imprinting
- Type
- article
- Field-Weighted Citation Impact
- 0.00